Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced it has
initiated the first phase of branding its lead drug candidate, Oncoprex(TM)
immunogene therapy, and has completed and submitted non-proprietary drug name
selections to the American Medical Association’s United States Adopted Names
(“USAN”) Council. According to the update, Genprex will, upon receipt of USAN
feedback expected later this year, submit its non-proprietary drug name
selections to the World Health Organization for International Nonproprietary Names
(“INN”) status. By mid-2020, the company expects to obtain an approved
non-proprietary drug name. “Developing and obtaining regulatory approval of a
non-proprietary drug name is a requirement for bringing our lead drug candidate
to market,” Genprex Chairman and CEO Rodney Varner said in the news release.
“We’re one step closer to achieving this regulatory milestone. An approved
non-proprietary drug name will also make our lead drug candidate more widely
recognizable to clinicians and physicians and most importantly, to patients
living with non-small cell lung cancer.”
To view the full press release, visit http://ibn.fm/8p8qJ
About Genprex Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung
cancer (NSCLC). Genprex’s platform technologies are designed to administer
cancer fighting genes by encapsulating them into nanoscale hollow spheres
called nanovesicles, which are then administered intravenously and taken up by tumor
cells where they express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts cell
signaling pathways that cause replication and proliferation of cancer cells,
re-establishes pathways for apoptosis, or programmed cell death, in cancer
cells, and modulates the immune response against cancer cells. Oncoprex has
also been shown to block mechanisms that create drug resistance. For more
information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
